MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis

MDRNA also reported its fourth-quarter financial results, posting lower operating costs on the elimination of non-RNAi programs and operations the company was working on prior to a corporate reorganization.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.